Hear cross-functional perspectives on successfully implementing AI across process development teams, from aligning with quality, IT, and manufacturing to overcoming cultural and technical barriers, with a focus on driving operational efficiency and long-term value

• How to mitigate inappropriate drug use and dosing risk, leveraging mechanisms like Pre-Approval Information Exchange (PIE) and PDUFA timelines to shape understanding of indication, value, and safety.
• How to engage payers as early as phase 2 to build trust and tailor future value-based contracts, launching with outcomes-driven frameworks to support access and reimbursement.

• Elucidating how researchers are using menstrual effluent to track fertility, inflammation, and disease.
• Consumer Adoption & Clinical Validation – The path to making menstrual-based diagnostics a mainstream health tool.
• Investment & Industry Growth – The market potential of menstrual-based biomarkers in diagnostics and therapeutics.

Equip teams with AI tools that capture process knowledge and simulate scale-up scenarios, reducing tech transfer timelines and improving first-batch success rates - critical for aligning R&D, MSAT, and manufacturing expectations early

Explore how ML-enabled real-time control systems and continuous process verification improve yield predictability, reduce rework, and enable faster release - offering a direct line of sight to cost savings and product quality gains

• Discussing the financial burden associated with contraception, gaps in coverage, and how this influences retail access.
• Sharing commercial opportunities by making low-cost contraception more available through ecosystem partnerships.
• How can the industry operationalize OTC coverage and distribution of contraception and other women’s health medications.

• Addressing the under-representation of women in cardiovascular studies and how data-driven clinical outcomes are essential for tailored treatments.
• How new technologies, screenings, and wearables are improving early detection and prevention of heart disease in women.
• How partnerships between healthcare providers, pharmaceutical companies, device, and tech companies, can drive better cardiovascular outcomes for women.